The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer
PDF
Cite
Share
Request
Invited Review
VOLUME: 54 ISSUE: 2
P: 256 - 263
2021

The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer

Acta Haematol Oncol Turc 2021;54(2):256-263
1. Department Of Oncology, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey
2.
No information available.
No information available
Received Date: 2021-07-17T11:57:35
Accepted Date: 2021-08-11T08:39:19
PDF
Cite
Share
Request

Abstract

Breast cancer is a heterogenous disease with various morphological, clinical and molecular features. Traditionally, pathologic parameters and clinical stage of the disease are used to determine indication of adjuvant treatment, however these features are not sufficient to identify the patients that need treatment. Prognostic and predictive biomarkers are needed to develop personalized treatments. Predictive factors are indicators of response to a particular treatment. MammaPrint® (Agendia, Amsterdam, the Netherlands), Oncotype DX® (Genomic Health, Redwood City, CA), Prosigna® (Nanostring technologies, Seattle, WA) and Endopredict® (Myriad Genetics) are gene expression profiles that are used to predict the benefit of adjuvant chemotherapy and provide additional prognostic and/or predictive information. In this review, we discuss the role of gene expression signatures in treatment decision of patients with breast cancer.

Keywords:
breast cancer, gene, recurrence score